Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363988 | 0.82 | ATM (0.47) | DRD4ERCC5FEN1SMN1; SMN2KMT2A | |
| SCHEMBL15239730 | 0.79 | GSK3B (0.54) | DRD4ALDH1A1ERCC5FEN1SMN1; SMN2 | |
| SCHEMBL15239732 | 0.79 | GSK3B (0.54) | DRD4ALDH1A1ERCC5FEN1SMN1; SMN2 | |
| SCHEMBL20342720 | 0.78 | SMN1; SMN2 (0.54) | DRD4ALDH1A1SMN1; SMN2KMT2ACTBP2 | |
| SCHEMBL3891431 | 0.74 | GSK3B (0.48) | DRD4ALDH1A1SMN1; SMN2KMT2AGAA | |
| SCHEMBL22024926 | 0.74 | GSK3B (0.48) | DRD4ALDH1A1SMN1; SMN2KMT2AGAA | |
| SCHEMBL6161952 | 0.74 | GSK3B (0.48) | DRD4ALDH1A1SMN1; SMN2KMT2AGAA | |
| SCHEMBL6443525 | 0.73 | MGLL (0.56) | SMN1; SMN2KMT2A | |
| SCHEMBL11172165 | 0.73 | MAOA (0.39) | DRD4ALDH1A1ERCC5FEN1SMN1; SMN2 | |
| SCHEMBL28344325 | 0.73 | DRD4 (0.40) | DRD4ERCC5FEN1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| EP-2595952-A1 | AGONISTS OF GPR40 | Connexios Life Sciences Pvt. Ltd. (IN) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012011125-A1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237571-A1 | AGONISTS OF GPR40 | GPR65, GPR55, GPR68 | DRD4 2029/4885ALDH1A1 2410/4885ERCC5 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.